In short. Donor sourcing, sterility and the injection route: how an unapproved tissue-derived product causes harm, and why a reported infection cannot be traced to a batch.
Key points
- Amniotic membrane used as a wound covering in a regulated setting and the same tissue injected as a cosmetic treatment are not the same intervention.
- Judging the second by the reputation of the first is the error at the centre of most of the marketing for these products.
Some products marketed for injection are derived from human birth tissue: the amniotic membrane, the placenta, the umbilical cord and the connective tissue around it. These materials are real, and they have legitimate uses. Amniotic membrane is used in regulated settings as a wound covering and in some surgical repairs. The question this guide addresses is what changes when material of that origin is injected, and why reports of harm cluster around the injection route rather than the material itself.
Why the route matters
A covering sits on a surface. An injection places material inside tissue, past the barrier that the skin provides, into a space where the immune system meets it directly and where any organism in the preparation has a route to spread. That difference is not a matter of degree. A preparation acceptable as a dressing may be entirely unsuitable as an injectable, for reasons that have nothing to do with the tissue and everything to do with where it is placed.
Sourcing and screening
Tissue from a donor has to be screened, and the screening has to be documented. Regulated tissue products carry that documentation: who the donor was, what was tested, how the material was processed, and how the risk of transmission was reduced. A product sold without an approval has no obligation to carry any of it, and a buyer has no way to check whether the screening happened at all.
The material and the injection are separate questions
Amniotic membrane used as a wound covering in a regulated setting and the same tissue injected as a cosmetic treatment are not the same intervention. Judging the second by the reputation of the first is the error at the centre of most of the marketing for these products.
Sterilisation and its tension
Treating tissue-derived material to reduce infection is not straightforward. The methods strong enough to destroy bacteria, fungi and viruses reliably tend to damage the proteins and other biological components that the product's claimed activity depends on. A manufacturer therefore faces a choice between a process validated for sterility and a process that preserves the material. Where no regulator has set the requirement, that choice is a commercial one, and the clinic receiving the vial has no way to know which was made.
Where a preparation is reconstituted in a clinic, from a powder or a concentrate, the opportunities for contamination multiply: the water, the container, the surface, and the hands. Sterility is a laboratory result, not an assumption.
Reports of harm have a common shape
- Infection at the injection site that spreads and needs prolonged treatment.
- No batch record, so the specific product cannot be identified or withdrawn.
- Other patients who received the same batch cannot be contacted, because nobody holds the list.
The harm reported here is not a subtle long-term question. It is an infection, in some cases a serious one, from a product that was never assessed for the way it was used.
Frequently asked questions
Why is a birth tissue product riskier injected than applied as a covering?
Because the route decides what the material meets. A covering sits on a surface that still has its barrier intact. An injection places the material inside tissue, past that barrier, where the immune system meets it directly and where any organism in the preparation has a route to spread. The same preparation can be acceptable as a dressing and unsuitable as an injectable.
What screening should a tissue-derived injectable have had?
A regulated tissue product carries documentation of who the donor was, what was tested, how the material was processed, and how the risk of transmission was reduced. The screening is the part that makes the material usable at all. A product sold without an approval has no obligation to carry any of that, and a buyer has no way to check whether it happened.
Why can a reported infection not be traced to a batch?
Because tracing needs three records that usually do not exist: what the product was, which batch it came from, and who received that batch. Without them an infection is an isolated event. The material cannot be tested, the other people who received the same vial cannot be contacted, and nothing can be withdrawn from use.
Risks & Limitations
- No product marketed as an exosome injectable has been through the approval process that would establish what it contains or what it does.
- Birth tissue derived material carries an infection risk when it is injected, and serious infections have been reported after such injections.
- The evidence behind most claims comes from laboratory work, animal models or uncontrolled case series, none of which establishes an effect in people.
- Regulatory status differs by country, and in most markets there is no approval for these products in any injectable use.
- Nothing on this site is a recommendation for or against any treatment, and it does not assess individual cases.
When to Seek Care
- Spreading redness, heat, swelling or discharge at an injection site: have it assessed promptly.
- Fever, or feeling unwell with a painful injected area: seek medical care without waiting.
- Severe or worsening pain, blistering, or skin breakdown where something was injected.
- Any new and persistent symptom after a treatment: have it assessed by a clinician who can examine you.
References & Further Reading
- American Society of Plastic Surgeons (ASPS) — procedure and safety guidance
- National Institute for Health and Care Excellence (NICE, UK) — relevant guidance
- Cochrane Library — systematic reviews
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.